Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment

Evidence supporting the routine, nonselective use of NGS in patients with sarcoma is currently limited. Given the complexity, the decision to perform an NGS panel, as well as the interpretation and use of its results for diagnostic or therapeutic purposes, should take place only in sarcoma-expert institutions, including a multidisciplinary review. The results of multigene panels performed in nonexpert sarcoma centers cannot replace the pathology review or the recommendation of NGS-guided therapies without prior evaluation by sarcoma experts.

Authors

Institutions

Publication Details

Journal
JAMA Oncology
Published
2025-10-16
DOI
https://doi.org/10.1001/jamaoncol.2025.3608
Citations
5
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
7.59
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment

Andrea Napolitano, Claudia Valverde, Carlo María Cicala, Javier Martín‐Broto et al.
5 citations
JAMA Oncology
Sarcoma Diagnosis and Treatment
7.59
article

Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment

Andrea Napolitano, Claudia Valverde, Carlo María Cicala, Javier Martín‐Broto, Angelo Paolo Dei Tos, Hans A. J. Gelderblom, Paolo G. Casali, William D. Tap, Jean‐Yves Blay, Anastasios Kyriazoglou, Khin Thway, Robin L. Jones, Eva Wardelmann, César Serrano, Winette T.A. van der Graaf, François Le Loarer, David J. Thomas, Silvia Stacchiotti, Piotr Rutkowski, Bernd Kasper, Judith V.M.G. Bovée, Antonia Digklia, Sebastian Bauer, Antoine Italiano
article en
5 citations

Abstract

Evidence supporting the routine, nonselective use of NGS in patients with sarcoma is currently limited. Given the complexity, the decision to perform an NGS panel, as well as the interpretation and use of its results for diagnostic or therapeutic purposes, should take place only in sarcoma-expert institutions, including a multidisciplinary review. The results of multigene panels performed in nonexpert sarcoma centers cannot replace the pathology review or the recommendation of NGS-guided therapies without prior evaluation by sarcoma experts.

JAMA OncologyVol. 11(12)
Université Claude Bernard Lyon 1 (FR), Royal Marsden NHS Foundation Trust (GB), Memorial Sloan Kettering Cancer Center (US), Garvan Institute of Medical Research (AU), University of Padua (IT), Université de Bordeaux (FR), University of Milan (IT), Heidelberg University (DE), Leiden University Medical Center (NL), Erasmus MC (NL), University Hospital Heidelberg (DE), The Netherlands Cancer Institute (NL), UNSW Sydney (AU), University Hospital Münster (DE), Centre Léon Bérard (FR), Essen University Hospital (DE), Royal Marsden Hospital (GB), Vall d'Hebron Hospital Universitari (ES), Institut Bergonié (FR), University General Hospital Attikon (GR), Erasmus MC Cancer Institute (NL), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), University Medical Centre Mannheim (DE), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Vall d'Hebron Institute of Oncology (ES), Deutsches Konsortium für Translationale Krebsforschung (DE), European Institute of Oncology (IT), University of Lausanne (CH)
Openalex Percentile: Top 2%
Sarcoma Diagnosis and Treatment
7.59
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.